PMI bids to gain first ever FDA modified-risk approval for iQOS

Philip Morris International (PMI) this week submitted its iQOS technology for approval as a reduced-risk product by the U.S. Food and Drug Administration (FDA), a strategy which if successful would provide a tremendous boost to the credibility of heat-not-burn and perhaps pave the way for PMI’s partner Altria to dominate that market in the United States. ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us